Innocutis launches buccal tablet for cold sores; New software tracks nanoparticles;

> Innocutis announced July 21 the launch of a 50 mg buccal tablet for cold sores. Release

> The FDA issued a warning about pure caffeine bulk bags marketed directly to consumers over the internet. A teaspoon of pure caffeine is about equivalent to 25 cups of coffee, and can easily cause an overdose, leading to dangerously erratic heartbeat, seizures and even death. Notice

> Malvern Instruments just launched NTA 3.0, an upgraded version of its software to track nanoparticles. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.